Repligen (NASDAQ:RGEN) Trading Up 5.4% – Here’s What Happened

Repligen Co. (NASDAQ:RGEN)’s share price traded up 5.4% during mid-day trading on Tuesday . The stock traded as high as $144.49 and last traded at $144.38. 133,624 shares were traded during trading, a decline of 79% from the average session volume of 637,420 shares. The stock had previously closed at $136.99.

Wall Street Analyst Weigh In

RGEN has been the topic of several research analyst reports. TD Cowen initiated coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $181.00.

Repligen Trading Down 0.9 %

The stock has a fifty day moving average price of $157.18 and a 200 day moving average price of $148.50. The stock has a market cap of $8.07 billion, a PE ratio of -285.75, a PEG ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Equities analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ballentine Partners LLC boosted its position in Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after purchasing an additional 72 shares in the last quarter. CIBC Asset Management Inc increased its holdings in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after acquiring an additional 81 shares in the last quarter. MML Investors Services LLC grew its position in Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after buying an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System grew its holdings in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after buying an additional 100 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.